Loading...
The anti-CD30 antibody–drug conjugate brentuximab vedotin (BV) has been incorporated into frontline therapy for adults with advanced-stage Hodgkin lymphoma (HL) and has been shown to be safe and effective in children with relapsed or refractory disease. In a randomized, multicenter, phase 3 trial, researchers compared five 3-week cycles of BV (1.8 mg/kg) plus doxorubicin, vincristine, etoposide, cyclophosphamide, and prednisone versus a standard regimen of the same chemotherapy agents plus bleomycin in patients ages 2 to 21 years with newly diagnosed bulky stage IIB, stage IIIB, or stage IVA/B HL. PET/CT was performed after cycle 2; patients with slow interim response and those with initial bulk disease received radiation therapy after comp…